genglob magazine

Helped by the government, the generic drugs business in Japan, the world’s second largest pharma market, is set to grow by 9% from the current less than 5% in the next 3-4 years.Indian generic makers see a huge opportunity as the generics market in Japan is poised to witness strong annual growth of around 9% in 2009-2013 on the back of strong government support and largely untapped nature. Leading Indian generic players, including Ranbaxy, Lupin, Zydus Cadila and Dishman, have already entered the Japanese pharma market. Read the rest of this entry »